HIMS Stock Retreats 7.33% as Traders Secure Profits
Hims & Hers Health (HIMS) shares closed at $23.15 on March 18, a 7.33% fall from the previous trading day. This downturn indicates that traders are taking profits after a period of significant appreciation. The move mirrors a similar drop on March 12, when the stock also fell nearly 8% on trading volume that was 126% above its three-month average, suggesting a pattern of investors selling into strength.
Novo Nordisk Lawsuit Resolution Ignited Prior Rally
The stock's recent strength was built on positive legal and analyst updates. The rally gained momentum after Novo Nordisk dropped its lawsuit against Hims concerning the sale of a compounded weight-loss drug. This resolution was viewed as a significant de-risking event, prompting investment bank Barclays on March 11 to reiterate its Overweight rating and increase its price target to $29 from $25. Barclays noted the market appeared to be underestimating opportunities from Hims' new product pipeline.
Digital Health Sector Faces Broader Headwinds
The decline in Hims' stock price did not happen in isolation. The broader digital health market also faced pressure, with competitors like Teladoc Health (TDOC) and American Well (AMWL) recording concurrent losses. While Hims has cleared a major legal hurdle and is pursuing an aggressive growth strategy with its own branded health products, investors remain focused on the inherent execution risks and potential for future litigation surrounding patent protections in the pharmaceutical space.
Edgen Stock·Mar 18 2026, 23:11
